PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer

NCT06320223 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital, Essen

Phase

Observational

Started

2024-03-05

Last updated

2024-03-20

Condition(s) studied

Prostate CancerPET/CTSurvivorshipPSMA

Study summary

Background:

PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.

Need:

Improved prognostication across various stages of prostate cancer is needed for management guidance and study design.

Aim:

1. To assess the prognostic value of PSMA PET
2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages

Inclusion:

* Adult patients with
* biopsy/histo proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.

Exclusion:

* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer

Eligibility

Sex

MALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer.

Primary outcome measure(s)

Overall survival — up to 10 years
Time from PSMA-PET until death

Trial sites (1)

Facility	City	Region	Status
University Hospital Essen	Essen	Germany	Recruiting

More University Hospital, Essen trials in Germany

Tourniquet-Test in HHT Active, not recruiting

Essen Coronary Artery Disease Registry Recruiting

Essen Amyloidosis Registry Recruiting

Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma Recruiting

Body Donation in HHT Recruiting

Other trials for the same condition

Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s) Recruiting

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer Active, not recruiting

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Active, not recruiting

Study of MR-based IGRT for Prostate Cancer Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06320223 on ClinicalTrials.gov ↗ ← All trials in Germany